Hypertension
Hypertension
Search
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
Pradaxa®
Prevention of strokes and blood clots in patients with abnormal heart rhythm (atrial fibrillation). Primary prevention of venous thrombo-embolic events (VTE) in adults after elective total hip or knee replacement surgery. Treatment of deep vein throm
Retinal Diseases
Retinal Diseases
Nurjanahs Story
Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
Advancing health equity for rural doctors in Mexico
Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location
It Takes 2
It Takes 2 people–a patient and a HCP, and 2 tests–a blood and a urine test–to help detect CKD. Early testing can drive earlier diagnosis and treatment.
Patient Safety & Pharmacovigilance at Boehringer Ingelheim
Patients inspire us in our mission to lead the science that creates breakthrough therapies, so that our medicines transform patients’ lives.
Acute Ischaemic Stroke
Acute Ischaemic Stroke
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Striving to revolutionize mental health research
World Mental Health Day: Through a precision psychiatry approach and rich pipeline, we are committed to transforming the mental health landscape.
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Retinal health: All eyes on vision loss
Discover how we want to prevent vision loss caused by diabetic retinopathy and other retinal diseases
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Facts About IPF
IPF is a debilitating and fatal lung disease.
Heart murmur in dogs: symptoms and how to treat it
Monitoring your dog’s heart can save its life
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
Tips to help you start your patient advocacy journey
Advocating for yourself as a patient can be daunting. Jeff Dunn, President of Union for International Cancer Control (UICC), shares some tips
Generalized pustular psoriasis at EADV 2021
Dr. Emmanuelle Clerisme-Beaty (former Associate Head of Medicine - Inflammation, Boehringer Ingelheim) reflects on developments for GPP at the EADV congress, 2021
New spesolimab data show significant improvement in GPP flares
New spesolimab data show significant improvement in GPP flares
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Spesolimab prevents GPP flares
Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.